Review
TAK-677 (Dainippon/Takeda)
Affiliations
- PMID: 12476963
Item in Clipboard
Review
TAK-677 (Dainippon/Takeda)
Curr Opin Investig Drugs.
2002 Nov.
Abstract
TAK-677 is a beta3-adrenergic agonist under development by Dainippon and Takeda for the potential treatment of non-insulin dependent diabetes and obesity. In March 2001, Takeda initiated a phase II trial in the US for Type II diabetes [411811], [416686], [423455]. By December 2001, the compound was also in phase II trials for obesity in the US, and Dainippon was conducting phase II studies in Japan for diabetes [458750].
Similar articles
-
Exenatide. Amylin/Eli Lilly.Curr Opin Investig Drugs. 2003 Apr;4(4):459-65. Curr Opin Investig Drugs. 2003. PMID: 12808888 Review.
-
Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.IDrugs. 2003 Sep;6(9):850-1. IDrugs. 2003. PMID: 14565170 No abstract available.
-
Evolution of peroxisome proliferator-activated receptor agonists.Ann Pharmacother. 2007 Jun;41(6):973-83. doi: 10.1345/aph.1K013. Epub 2007 May 22. Ann Pharmacother. 2007. PMID: 17519293 Review.
-
Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.Bioorg Med Chem Lett. 2007 Sep 15;17(18):5245-50. doi: 10.1016/j.bmcl.2007.06.072. Epub 2007 Jun 30. Bioorg Med Chem Lett. 2007. PMID: 17632003
-
Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.Ann Pharmacother. 2004 Jan;38(1):30-5. doi: 10.1345/aph.1C397. Ann Pharmacother. 2004. PMID: 14742789 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous